K

Kriya Therapeutics

Develops gene therapies; licenses collaborations

Senior Vice President - Biometrics

Quantitative Biology & BiostatisticsUpdated on Nov 14
Full-timeNorth Carolina, USANo salary listed

About the Job

Requirements

  • A PhD in Biostatistics, Statistics, or a related quantitative field is required; an MS may be considered with exceptional experience.
  • At least 15 years of biometrics experience in the biotechnology or pharmaceutical industry, including at least 7 years leading biometrics organizations.
  • A proven track record leading biometrics for successful regulatory submissions (NDA/BLA/MAA) and approvals.
  • Deep knowledge of CDISC standards, ICH guidelines, FDA and EMA expectations, and statistical methodology for novel and adaptive designs.
  • Demonstrated experience with health authority interactions, DSMB support, and inspection readiness.
  • Technical proficiency with SAS, R, and statistical programming (SDTM, ADaM, TLFs), plus oversight of clinical data management and EDC.
  • Experience managing CRO and vendor relationships and building scalable systems and processes.
  • Ability to communicate complex statistical concepts clearly to cross-functional leaders, regulators, and investors.
  • Strategic thinking that connects data and statistical strategy to program value.
  • Ability to lead, build, and scale teams, and to develop talent.
  • Accountability for quality, timelines, and budget.

Responsibilities

  • Define and execute the biometrics vision, operating model, and multi-year roadmap aligned to the clinical development plan; serve on the clinical development leadership team and represent Biometrics to executive management and the Board as needed.
  • Provide statistical leadership for trial design, sample size, endpoint selection, adaptive and Bayesian methods, interim analyses, and statistical analysis plans across all programs; lead use of natural history data, external controls, and real-world evidence to support development and regulatory strategy.
  • Lead biometrics content and strategy for FDA, EMA, and other health authority interactions, including pre-IND, End-of-Phase meetings, Scientific Advice, INDs, and BLAs/MAAs; ensure submission-ready datasets, ADaM/SDTM packages, and define files meet CDISC and agency standards.
  • Oversee SDTM and ADaM development, TLFs, integrated summaries, and programming validation; establish standards, metadata repositories, and reusable macros to support quality and speed.
  • Partner with Clinical Safety and Clinical Operations on long-term follow-up data strategy for gene therapy programs, including DSMB and independent data monitoring committee support.
  • Select, govern, and manage CROs and technology vendors for biometrics services, with performance metrics, quality agreements, and budget accountability.
  • Ensure high-quality, inspection-ready data collection, cleaning, and database lock across internal and CRO-managed studies; oversee EDC selection and build, data review, external data integration, and risk-based quality management.
  • Ensure compliance with GCP, ICH, 21 CFR Part 11, and applicable data privacy requirements; maintain inspection readiness and lead biometrics participation in audits and inspections.
  • Lead, develop, and retain a high-performing team; build a scalable organization through the transition from a development-stage company to a commercial-ready one; manage functional budgets and resource planning.

Desired Qualifications

  • Experience with cell and gene therapy, rare disease, or ophthalmology, cardiology, or neurology programs is strongly preferred.

About the Company

Kriya Therapeutics

Develops gene therapies; licenses collaborations

Kriya Therapeutics develops gene therapies for widespread diseases and monetizes these programs through licensing and collaboration agreements. Its gene therapies target genetic or biological drivers of conditions such as Geographic Atrophy, Diabetic Retinopathy, and NASH, with a focus on ophthalmology. The company advances programs by partnering with biotech and pharma companies to secure upfront payments, milestones, and potential royalties. Its goal is to become a leading gene therapy biopharmaceutical company by delivering safe, effective treatments and generating revenue through collaborations and eventual product sales.

Company size
201-500
Company stage
Series D
Total funding
$920.5M
Headquarters
Morrisville, NC
Founded
2019

Recently Posted Jobs

Explore more opportunities at Kriya Therapeutics

See more jobs